Glenmede Trust
BEAM icon

Glenmede Trust’s Beam Therapeutics BEAM Stock Holding History

Glenmede Trust’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,552
Closed -$216K – 1287
2022
Q3 		$216K Buy
+4,552
New +$260K ﹤0.01% 1065
2022
Q2 		– Sell
-7,437
Closed -$425K – 1296
2022
Q1 		$425K Buy
7,437
+50
+0.7% +$3.28K ﹤0.01% 944
2021
Q4 		$588K Buy
7,387
+100
+1% +$8.56K ﹤0.01% 879
2021
Q3 		$633K Sell
7,287
-56
-0.8% -$5.63K ﹤0.01% 831
2021
Q2 		$945K Buy
7,343
+2,903
+65% +$231K ﹤0.01% 717
2021
Q1 		$355K Buy
4,440
+1,440
+48% +$137K ﹤0.01% 936
2020
Q4 		$244K Hold
3,000
– – ﹤0.01% 1010
2020
Q3 		$73K Buy
+3,000
New +$74.4K ﹤0.01% 1251

Other funds holding BEAM

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Glenmede Trust's BEAM Position: Q4 2022 in Review

Glenmede Trust sold out of Beam Therapeutics (BEAM) in Q4 2022, closing a stake of 4,552 shares — an estimated $216K sold.

Glenmede Trust first reported a position in BEAM in Q3 2020 and held it in 8 quarters. The position peaked at $945K in Q2 2021. 207 funds tracked by Wall St. Rank hold BEAM as of Q4 2022.

  • Glenmede Trust reported no remaining Beam Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Glenmede Trust sold 4,552 Beam Therapeutics shares in Q4 2022, an estimated $216K.
  • Glenmede Trust first reported a position in Beam Therapeutics in Q3 2020 and held it in 8 quarters.
  • Glenmede Trust's Beam Therapeutics position peaked at $945K in Q2 2021.
  • 207 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2022.

Based on Glenmede Trust's 13F filing for Q4 2022, filed 14 Feb 2023.